GKIM
BBIO icon

GW&K Investment Management’s BridgeBio Pharma BBIO Stock Holding History

GW&K Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.8M Buy
1,125,131
+162,488
+17% +$11.4M 0.65% 37
2026
Q1 		$71.5M Buy
962,643
+336,521
+54% +$24.4M 0.63% 36
2025
Q4 		$47.9M Buy
626,122
+27,885
+5% +$1.83M 0.41% 89
2025
Q3 		$31.1M Buy
+598,237
New +$29.2M 0.27% 141

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

GW&K Investment Management's BBIO Position: Q2 2026 in Review

GW&K Investment Management increased its BridgeBio Pharma (BBIO) stake by 17% in Q2 2026, buying an estimated $11.4M and bringing the position to 1,125,131 shares worth $83.8M. The position accounts for 0.65% of the portfolio, ranked #37.

GW&K Investment Management first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • GW&K Investment Management held 1,125,131 shares of BridgeBio Pharma worth $83.8M as of Q2 2026.
  • GW&K Investment Management bought 162,488 BridgeBio Pharma shares in Q2 2026, an estimated $11.4M.
  • BridgeBio Pharma made up 0.65% of GW&K Investment Management's portfolio in Q2 2026, its #37 holding.
  • GW&K Investment Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.